Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-36. (Cancelled)

37. (Previously presented) A compound which is 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one or a pharmaceutically acceptable salt thereof.

38. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 37, or a pharmaceutically acceptable salt thereof, in admixture with one or more pharmaceutically acceptable carriers or excipients.

39-40. (Cancelled)

41. (New) A pharmaceutical composition according to claim 38 wherein the pharmaceutical composition is formulated for oral administration.

42. (New) A pharmaceutical composition according to claim 41 in the form of a tablet or capsule.

43. (New) A pharmaceutical composition according to claim 42 in the form of a tablet.

44. (New) A pharmaceutical composition according to claim 43 wherein the tablet is coated.

45. (New) A pharmaceutical composition according to claim 41 formulated to give controlled release of 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one or a pharmaceutically acceptable salt thereof.

46. (New) A pharmaceutical composition according to claim 41 wherein at least one pharmaceutically acceptable excipient is selected from the group consisting of binding agents, fillers, lubricants, disintegrants, wetting agents, suspending agents, emulsifying agents, non-aqueous vehicles, preservatives, buffer salts, flavouring agents, coloring agents, and sweetening agents.

47. (New) A pharmaceutical composition according to claim 46 wherein at least one pharmaceutically acceptable excipient is selected from the group consisting of binding agents, fillers, lubricants, disintegrants, and wetting agents.

48. (New) A compound which is 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one.

49. (New) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 48 in admixture with one or more pharmaceutically acceptable carriers or excipients.

50. (New) A pharmaceutical composition according to claim 49 wherein the pharmaceutical composition is formulated for oral administration.

51. (New) A pharmaceutical composition according to claim 50 in the form of a tablet or capsule.

52. (New) A pharmaceutical composition according to claim 51 in the form of a tablet.

53. (New) A pharmaceutical composition according to claim 52 wherein the tablet is coated.

54. (New) A pharmaceutical composition according to claim 50 formulated to give controlled release of 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one.

55. (New) A pharmaceutical composition according to claim 50 wherein at least one pharmaceutically acceptable excipient is selected from the group consisting of binding agents, fillers, lubricants, disintegrants, wetting agents, suspending agents, emulsifying agents, non-aqueous vehicles, preservatives, buffer salts, flavouring agents, coloring agents, and sweetening agents.

56. (New) A pharmaceutical composition according to claim 55 wherein at least one pharmaceutically acceptable excipient is selected from the group consisting of binding agents, fillers, lubricants, disintegrants, and wetting agents.